Feasibility of Generating Novel Therapeutic Strategies Based on Evolutionary Tumor Board in Cancer Patients
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 35
- 试验地点
- 1
- 主要终点
- ETB developing therapeutic strategies
研究概览
简要总结
This study will evaluate the ability of a multidisciplinary group, the Evolutionary Tumor Board (ETB), to develop therapeutic strategies in patients without curative options.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participant must be considered likely incurable given a standard of care. This is inclusive of participants in remission but at high risk of recurrence, with suboptimal responses to previous therapy, or with many potentially beneficial, but not curative options for care.
- •Participant must have a life expectancy greater than 3 months
- •Participant must have an ECOG performance status 0-2
- •Participant and primary Oncologist are willing to consider the therapeutic strategies recommended by the ETB
- •Willingness to be followed over time and allowing collection of clinical data including scans and serial blood sampling.
排除标准
- 未提供
研究组 & 干预措施
Participants Reviewed by ETB
Participants clinical history, available therapeutic options, and outcome expectations will be presented to the Evolutionary Tumor Board (ETB) along with images and pathology. Strategies and models will be presented regarding additional evolutionary ideas that can be applied.
干预措施: Evolutionary Tumor Board (ETB) (Other)
结局指标
主要结局
ETB developing therapeutic strategies
时间窗: Baseline to up to 60 months from end of therapy
The investigators want to demonstrate the ability of a multidisciplinary group, the ETB, to develop therapeutic strategies in participants without curative options. They plan to enroll 35 patients to this study over 3 years. The primary objective will be successfully met if they can develop an evolutionary based plan that differs from the participants options prior to presentation for at least 80%, or 28 of these participants.
次要结局
未报告次要终点